Results 251 to 260 of about 199,032 (289)
Correction: Meta-analysis of tuberculosis incidence and risk in cancer patients treated with immune checkpoint inhibitors. [PDF]
Front OncolMing H, Fu B, Chen X, Hu W, Yu H.
europepmc +1 more source
Histologic Features of Melanocytic Nevi Secondary to Melanoma Treatment With Immune Checkpoint Inhibitors. [PDF]
CureusSohail N +6 more
europepmc +1 more source
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Before and After Liver Transplantation: A Systematic Review. [PDF]
Cancers (Basel)Dituri F +4 more
europepmc +1 more source
Metformin enhances survival with immune checkpoint inhibitors in cancer patients: A meta-analysis. [PDF]
Oncol LettQiao Y, Li H, Feng Y, Liang S, Hua D.
europepmc +1 more source
Immune Checkpoint Inhibitors in Gliomas
Current Oncology Reports, 2017 Malignant gliomas result in disproportionately high morbidity and mortality compared with other primary tumors, and progression of disease is inevitable. Novel therapies to improve outcomes are needed and immune checkpoint inhibitors hold significant promise.A limited body of preclinical evidence suggests that checkpoint inhibitors may be effective ...
Aaron C, Tan +2 more
openaire +3 more sources
Immune Checkpoint Inhibitors in Prostate Cancer
Cancers, 2021 Metastatic prostate cancer is a lethal disease with limited treatment options. Immune checkpoint inhibitors have dramatically changed the treatment landscape of multiple cancer types but have met with limited success in prostate cancer.
Umang Swami, Agarwal Neeraj
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Immune Checkpoint Inhibitors in the Aged
Current Oncology Reports, 2021Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs +2 more
openaire +2 more sources
Immune checkpoint inhibitors and vasculitis
Current Opinion in Rheumatology, 2020Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland +2 more
openaire +2 more sources